Sara Magni
University of Pavia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sara Magni.
Nanomedicine: Nanotechnology, Biology and Medicine | 2015
Emanuela Cova; Miriam Colombo; Simona Inghilleri; Monica Morosini; Simona Miserere; Jesus Peñaranda-Avila; Benedetta Santini; Davide Piloni; Sara Magni; Furio Gramatica; Davide Prosperi; Federica Meloni
AIMS Chronic lung allograft dysfunction represents the main cause of death after lung transplantation, and so far there is no effective therapy. Mesenchymal cells (MCs) are primarily responsible for fibrous obliteration of small airways typical of chronic lung allograft dysfunction. Here, we engineered gold nanoparticles containing a drug in the hydrophobic section to inhibit MCs, and exposing on the outer hydrophilic surface a monoclonal antibody targeting a MC-specific marker (half-chain gold nanoparticles with everolimus). MATERIALS & METHODS Half-chain gold nanoparticles with everolimus have been synthesized and incubated with MCs to evaluate the effect on proliferation and apoptosis. RESULTS & DISCUSSION Drug-loaded gold nanoparticles coated with the specific antibody were able to inhibit proliferation and induce apoptosis without stimulating an inflammatory response, as assessed by in vitro experiments. CONCLUSION These findings demonstrate the effectiveness of our nanoparticles in inhibiting MCs and open new perspectives for a local treatment of chronic lung allograft dysfunction.
Transplant Immunology | 2016
Davide Piloni; Sara Magni; Tiberio Oggionni; Alberto Benazzo; Giulia Stella; Luigia Scudeller; Monica Morosini; Emanuela Cova; Federica Meloni
The ImmuKnow assay measures cell-mediated immunity, quantifying ATP production from peripheral blood CD4+T-cells in solid-organ transplant patients who undergo immunosuppressive therapy. We aimed to measure functional immunity in lung transplant recipients and correlate Immuknow values with immunosuppression levels, presence of chronic lung allograft dysfunction (CLAD) and infections. We evaluated 61 lung recipients who underwent follow-up for lung transplantation between 2010 and 2014. Rejection and infection were retrospectively analyzed. The association between over-immunosuppression and a number of predictors was assessed by means of univariate and multivariate logistic regression models. 71 out of 127 samples (56%) showed an over-immunosuppression with an ImmuKnow assay mean level of 112.92ng/ml (SD±58.2), vs. 406.14ng/ml (SD±167.7) of the rest of our cohort. In the over-immunosuppression group we found 51 episodes of infection (71%) (OR 2.754, 95% CI 1.40-5.39; P-value 0.003). In the other group, only 25 samples (44%) were taken during an infectious episode. The mean absolute ATP level was significantly different between patients with or without infection (202.38±139.06ng/ml vs. 315.51±221.60ng/ml; P<0.001). RAS (Restrictive allograft syndrome) was associated to low ImmuKnow level (P<0.001). These results were confirmed by the multivariate analysis. The ImmuKnow assay levels were significantly lower in infected lung transplant recipients compared with non-infected recipients and in RAS patients.
Nanotoxicology | 2017
Emanuela Cova; Simona Inghilleri; Laura Pandolfi; Monica Morosini; Sara Magni; Miriam Colombo; Davide Piloni; Chiara Finetti; Gabriele Ceccarelli; Laura Benedetti; Maria Gabriella Cusella; Manuela Agozzino; Fabio Corsi; Raffaele Allevi; Simona Mrakic-Sposta; Sarah Moretti; Simona De Gregori; Davide Prosperi; Federica Meloni
Abstract The use of gold nanoparticles (GNPs) as drug delivery system represents a promising issue for diseases without effective pharmacological treatment due to insufficient local drug accumulation and excessive systemic toxicity. Bronchiolitis obliterans syndrome (BOS) represents about 70% of cases of chronic lung allograft dysfunction, the main challenge to long-term lung transplantation. It is believed that due to repeated insults to epithelial bronchiolar cells local inflammatory response creates a milieu that favors epithelial–mesenchymal transition and activation of local mesenchymal cells (MCs) leading to airway fibro-obliteration. In a previous work, we engineered GNPs loaded with the mammalian target of rapamycin inhibitor everolimus, specifically decorated with an antibody against CD44, a surface receptor expressed by primary MCs isolated from bronchoalveolar lavage of BOS patients. We proved in vitro that these GNPs (GNP-HCe) were able to specifically inhibit primary MCs without affecting the bronchial epithelial cell. In the present work, we investigated the effect of these bioengineered nanoconstructs on inflammatory cells, given that a stimulating effect on macrophages, neutrophils or lymphocytes is strongly unwanted in graft airways since it would foster fibrogenesis. In addition, we administered GNP-HCe by the inhalatory route to normal mice for a preliminary assessment of their pulmonary and peripheral (liver, spleen and kidney) uptake. By these experiments, an evaluation of tissue toxicity was also performed. The present study proves that our bioengineered nanotools do not rise an inflammatory response and, under the tested inhalatory conditions that were used, are non-toxic.
BMC Pulmonary Medicine | 2017
Davide Piloni; Monica Morosini; Sara Magni; Alice Balderacchi; Luigia Scudeller; Emanuela Cova; Tiberio Oggionni; Giulia Stella; Carmine Tinelli; Filippo Antonacci; Andrea Maria D’Armini; Federica Meloni
European Respiratory Journal | 2016
Cristina Airoldi; Carlotta Ciaramelli; Marco Fumagalli; Sara Magni; Simona Viglio; Davide Piloni; Annamaria Bardoni; Paolo Iadarola; Federica Meloni
European Respiratory Journal | 2017
Emanuela Cova; Simona Inghilleri; Davide Piloni; Monica Morosini; Laura Pandolfi; Miriam Colombo; Simona Mrakic-Sposta; Sarah Moretti; Sara Magni; Davide Prosperi; Federica Meloni
European Respiratory Journal | 2017
Davide Piloni; Ilaria Ferrarotti; Simona Viglio; Maddalena Cagnoni; Marina Gorrini; Sara Magni; Monica Di Venere; Roberta Salvini; Anna Bardoni; Paolo Iadarola; Federica Meloni
Journal of Heart and Lung Transplantation | 2016
Davide Piloni; Monica Morosini; Sara Magni; A. Balderacchi; L. Scudeller; Emanuela Cova; Tiberio Oggionni; G. Stella; Carmine Tinelli; F. Antonacci; Federica Meloni
European Respiratory Journal | 2016
Davide Piloni; Monica Morosini; Sara Magni; Alice Balderacchi; Emanuela Cova; Simona Inghilleri; Luigia Scudeller; Tiberio Oggionni; Filippo Antonacci; Giulia Stella; Federica Meloni
European Respiratory Journal | 2016
Emanuela Cova; Simona Inghilleri; Davide Piloni; Veronica Codullo; Laura Pandolfi; Miriam Colombo; Monica Morosini; Valentina Barzon; Sara Magni; Davide Prosperi; Carlomaurizio Montecucco; Federica Meloni